VIVEKANANDA RACHAMALLU: Open Payments
NPI 1942687470 · ERLANGER, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$458 in 23 payments from 8 companies in 2025. Trend: 2023 $276 · 2024 $600 · 2025 $458
Food & beverage: $458
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 6 | $116 |
| Teva Pharmaceuticals USA, Inc. | 5 | $98 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $68 |
| Luye Pharma (USA) Ltd. | 3 | $59 |
| Noven Therapeutics, LLC | 2 | $42 |
| ABBVIE INC. | 1 | $32 |
| Indivior Inc. | 1 | $25 |
| Neurocrine BioSciences, Inc. | 1 | $18 |
Products named: AUSTEDO XR, ABILIFY MAINTENA, CAPLYTA, ERZOFRI EXTENDED-RELEASE, VRAYLAR, SUBLOCADE, ABILIFY ASIMTUFII, Xelstrym.
Industry payments across KY — which companies pay providers there.
